DexCom vs Zoetis Which Is Stronger?

DexCom and Zoetis are two prominent companies in the healthcare industry with stocks that have attracted the attention of investors. DexCom specializes in continuous glucose monitoring systems for people with diabetes, while Zoetis is a leader in animal health products and services. Both companies have shown strong growth potential in their respective markets, making them popular choices for investors looking to capitalize on the growing demand for innovative healthcare solutions. Understanding the key differences and similarities between DexCom and Zoetis stocks is essential for making informed investment decisions in this dynamic sector.

DexCom or Zoetis?

When comparing DexCom and Zoetis, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between DexCom and Zoetis.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. DexCom has a dividend yield of -%, while Zoetis has a dividend yield of 1.23%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. DexCom reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Zoetis reports a 5-year dividend growth of 24.37% year and a payout ratio of 31.44%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with DexCom P/E ratio at 40.71 and Zoetis's P/E ratio at 32.83. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. DexCom P/B ratio is 14.01 while Zoetis's P/B ratio is 15.24.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, DexCom has seen a 5-year revenue growth of 2.21%, while Zoetis's is 0.54%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with DexCom's ROE at 31.20% and Zoetis's ROE at 47.99%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $69.66 for DexCom and $175.00 for Zoetis. Over the past year, DexCom's prices ranged from $62.34 to $142.00, with a yearly change of 127.78%. Zoetis's prices fluctuated between $144.80 and $201.92, with a yearly change of 39.45%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.